Vivos Therapeutics, Inc. (VVOS) announced on Wednesday that it has obtained 510(k) clearance from the FDA for its DNA oral medical device aimed at treating moderate to severe obstructive sleep apnea and snoring in children. The stock is currently up by 17% in pre-market trading.
The FDA's approval follows a multi-site clinical trial that demonstrated significant improvements in children aged 6 to 17 in symptoms of obstructive sleep apnea and airway volumes using the company's DNA appliance. Key results from the study show a 50% reduction in sleep-related breathing disorder symptoms, a 58% decrease in snoring, a 62.7% improvement in moderate and severe AHI measurements, and a 40% increase in airway volumes.
The company stated that this marks what is believed to be the first clearance for an oral medical device targeting pediatric OSA treatment.
In pre-market activity on the Nasdaq, the shares are trading at $3.19, up 17.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.